chr1-161506414-C-T
Position:
Variant summary
Our verdict is Benign. Variant got -16 ACMG points: 0P and 16B. BP6_Very_StrongBA1
The NM_001136219.3(FCGR2A):c.187C>T(p.Gln63*) variant causes a stop gained change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.112 in 1,614,092 control chromosomes in the GnomAD database, including 11,453 homozygotes. In-silico tool predicts a benign outcome for this variant. Variant has been reported in ClinVar as Benign (★★). Variant results in nonsense mediated mRNA decay.
Frequency
Genomes: 𝑓 0.090 ( 849 hom., cov: 32)
Exomes 𝑓: 0.11 ( 10604 hom. )
Consequence
FCGR2A
NM_001136219.3 stop_gained
NM_001136219.3 stop_gained
Scores
7
Clinical Significance
Conservation
PhyloP100: -0.500
Genes affected
FCGR2A (HGNC:3616): (Fc gamma receptor IIa) This gene encodes one member of a family of immunoglobulin Fc receptor genes found on the surface of many immune response cells. The protein encoded by this gene is a cell surface receptor found on phagocytic cells such as macrophages and neutrophils, and is involved in the process of phagocytosis and clearing of immune complexes. Alternative splicing results in multiple transcript variants. [provided by RefSeq, Oct 2008]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Benign. Variant got -16 ACMG points.
BP6
Variant 1-161506414-C-T is Benign according to our data. Variant chr1-161506414-C-T is described in ClinVar as [Benign]. Clinvar id is 402852.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr1-161506414-C-T is described in Lovd as [Benign].
BA1
GnomAd4 highest subpopulation (NFE) allele frequency at 95% confidence interval = 0.12 is higher than 0.05.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
FCGR2A | NM_001136219.3 | c.187C>T | p.Gln63* | stop_gained | 3/7 | ENST00000271450.12 | NP_001129691.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
FCGR2A | ENST00000271450.12 | c.187C>T | p.Gln63* | stop_gained | 3/7 | 1 | NM_001136219.3 | ENSP00000271450.6 |
Frequencies
GnomAD3 genomes AF: 0.0897 AC: 13645AN: 152118Hom.: 847 Cov.: 32
GnomAD3 genomes
AF:
AC:
13645
AN:
152118
Hom.:
Cov.:
32
Gnomad AFR
AF:
Gnomad AMI
AF:
Gnomad AMR
AF:
Gnomad ASJ
AF:
Gnomad EAS
AF:
Gnomad SAS
AF:
Gnomad FIN
AF:
Gnomad MID
AF:
Gnomad NFE
AF:
Gnomad OTH
AF:
GnomAD3 exomes AF: 0.104 AC: 26117AN: 251418Hom.: 1800 AF XY: 0.109 AC XY: 14744AN XY: 135878
GnomAD3 exomes
AF:
AC:
26117
AN:
251418
Hom.:
AF XY:
AC XY:
14744
AN XY:
135878
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.114 AC: 166943AN: 1461856Hom.: 10604 Cov.: 32 AF XY: 0.115 AC XY: 83596AN XY: 727228
GnomAD4 exome
AF:
AC:
166943
AN:
1461856
Hom.:
Cov.:
32
AF XY:
AC XY:
83596
AN XY:
727228
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome AF: 0.0896 AC: 13647AN: 152236Hom.: 849 Cov.: 32 AF XY: 0.0902 AC XY: 6714AN XY: 74438
GnomAD4 genome
AF:
AC:
13647
AN:
152236
Hom.:
Cov.:
32
AF XY:
AC XY:
6714
AN XY:
74438
Gnomad4 AFR
AF:
Gnomad4 AMR
AF:
Gnomad4 ASJ
AF:
Gnomad4 EAS
AF:
Gnomad4 SAS
AF:
Gnomad4 FIN
AF:
Gnomad4 NFE
AF:
Gnomad4 OTH
AF:
Alfa
AF:
Hom.:
Bravo
AF:
TwinsUK
AF:
AC:
459
ALSPAC
AF:
AC:
471
ESP6500AA
AF:
AC:
128
ESP6500EA
AF:
AC:
1131
ExAC
AF:
AC:
12529
Asia WGS
AF:
AC:
117
AN:
3478
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Benign
Submissions summary: Benign:3
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
not specified Benign:1
Benign, criteria provided, single submitter | clinical testing | Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine | Mar 28, 2016 | Variant identified in a genome or exome case(s) and assessed due to predicted null impact of the variant or pathogenic assertions in the literature or databases. Disclaimer: This variant has not undergone full assessment. The following are preliminary notes: Frequency - |
not provided Benign:1
Benign, criteria provided, single submitter | not provided | Breakthrough Genomics, Breakthrough Genomics | - | - - |
FCGR2A-related disorder Benign:1
Benign, no assertion criteria provided | clinical testing | PreventionGenetics, part of Exact Sciences | Jan 10, 2020 | This variant is classified as benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
BayesDel_addAF
Benign
T
BayesDel_noAF
Benign
CADD
Pathogenic
DANN
Benign
Eigen
Benign
Eigen_PC
Benign
FATHMM_MKL
Benign
N
Vest4
GERP RS
RBP_binding_hub_radar
RBP_regulation_power_radar
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at